Rilvegostomig plus T-DXd achieved 57% pCR in HR+/immune+ HER2-negative breast cancer in I-SPY 2.2, potentially enabling surgery without chemotherapy. In this study, R, a bispecific checkpoint ...
Enfortumab vedotin monotherapy or its combination with pembrolizumab could significantly evolve the treatment landscape for urothelial cancer. Arlene Siefker-Radtke, MD: Looking at the data presented, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results